← Back to Clinical Trials
Recruiting NCT03718364

NCT03718364 Swiss Atrial Fibrillation Pulmonary Vein Isolation Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03718364
Status Recruiting
Phase
Sponsor University Hospital, Basel, Switzerland
Condition Catheter-based Ablation of Atrial Fibrillation
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 2010-07-01
Primary Completion 2035-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
catheter-based ablation of atrial fibrillation (pulmonary vein isolation)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,000 participants in total. It began in 2010-07-01 with a primary completion date of 2035-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Registry of patients with atrial fibrillation undergoing catheter-based ablation of atrial fibrillation (pulmonary vein isolation) to determine long-term success rates of catheter-based ablation of atrial fibrillation (pulmonary vein isolation) and to evaluate factors associated with long-term success of catheter-based ablation of atrial fibrillation (pulmonary vein isolation).

Eligibility Criteria

Inclusion Criteria: * patients undergoing catheter-based ablation of atrial fibrillation (pulmonary vein isolation) Exclusion Criteria: * Patients not able or willing to participate in this study

Contact & Investigator

Central Contact

Michael Kuehne, MD

✉ michael.kuehne@usb.ch

📞 +41 61 328 74 71

Principal Investigator

Michael Kuehne, MD

PRINCIPAL INVESTIGATOR

Cardiology/Electrophysiology, University Hospital Basel

Frequently Asked Questions

Who can join the NCT03718364 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Catheter-based Ablation of Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03718364 currently recruiting?

Yes, NCT03718364 is actively recruiting participants. Contact the research team at michael.kuehne@usb.ch for enrollment information.

Where is the NCT03718364 trial being conducted?

This trial is being conducted at Basel, Switzerland, Bern, Switzerland.

Who is sponsoring the NCT03718364 clinical trial?

NCT03718364 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Michael Kuehne, MD at Cardiology/Electrophysiology, University Hospital Basel. The trial plans to enroll 3,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology